AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18082486 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clopidogrel and acetylsalicylic acid
Number of subjects: 0
Study 18082486 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulant
Number of subjects: 0
Study 18083847 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase-dependent cytochrome c-related activation of caspase-3 (CRAC(dep)) positive patients (intact signaling)
Number of subjects: 45
Study 18083847 — intervention group
Group type: COMPARATOR
Intervention: CRAC(dep) negative patients (deficient signaling)
Number of subjects: 45
Study 18084623 — intervention group
Group type: EXPERIMENTAL
Intervention: IV bolus injection of ferumoxytol (carboxymethyl dextran-based magnetic nanoparticle)
Number of subjects: 10
Study 18084743 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg BID
Number of subjects: 1767
Study 18084743 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (sustained release) 150 mg BID
Number of subjects: 1767
Study 18084743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1767
Study 18089335 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (50 to 100 mg/day) for invasive candidiasis (IC)
Number of subjects: 22
Study 18089335 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (50 to 100 mg/day) for invasive aspergillosis (IA)
Number of subjects: 22
Study 18089335 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin (50 to 100 mg/day)
Number of subjects: 22
Study 18089985 — intervention group
Group type: EXPERIMENTAL
Intervention: INSPIRE intervention
Number of subjects: 40
Study 18089985 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study 18089990 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention trial (2001-2005)
Number of subjects: 1126
Study 18090358 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol levels
Number of subjects: 301
Study 18090358 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol quartiles
Number of subjects: 301
Study 18090358 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol level of 100 pg/mL
Number of subjects: 301
Study 18090508 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg/day for 3 weeks after a 1-week titration at 10 mg/day, then increased to a maximum of 50 mg/day for 12 weeks if needed)
Number of subjects: 67
Study 18090508 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (high-dose, mean dose 33.8 mg/day at endpoint)
Number of subjects: 67
Study 18091520 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 728
Study 18093207 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily)
Number of subjects: 1855
Study 18096059 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (20 mg/m2) and topotecan (escalating doses of 2, 2.5, 3, 3.5, and 4 mg/m2) administered on days 1 and 8 every 21 days
Number of subjects: 18
Study 18155707 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitution of aspartic acid to nonaspartic acid at residue 57 of DQbeta1
Number of subjects: 40
Study 18155707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaspartic acid homozygosity at DQbeta1 57
Number of subjects: 40
Study 18155707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaspartic acid heterozygosity at DQbeta1 57
Number of subjects: 40
Study 18162025 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of substance use disorder (SUD)
Number of subjects: 4010
Study 18162025 — intervention group
Group type: COMPARATOR
Intervention: No family history of substance use disorder (SUD)
Number of subjects: 4010
Study 18163417 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 6610
Study 18163506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIGs) administered at 0.5 gm/kg/day for 4 days, as additional therapy administered monthly for 6 months.
Number of subjects: 22
Study 18165388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical balloon placement
Number of subjects: 69
Study 18165388 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine balloon placement
Number of subjects: 69
Study 18165388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulliparous women
Number of subjects: 69
Study 18166563 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance (50-105 mg/day)
Number of subjects: 16
Study 18166563 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 16
Study 18166563 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 16
Study 18174826 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT1 genotype
Number of subjects: 29
Study 18174826 — intervention group
Group type: COMPARATOR
Intervention: Stimulant medication (implied as a comparison)
Number of subjects: 29
Study 18178411 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hemoglobin (<12.1 g/dl)
Number of subjects: 48612
Study 18178411 — intervention group
Group type: COMPARATOR
Intervention: High hemoglobin (highest quartile)
Number of subjects: 48612
Study 18178412 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP >or=840 pg/ml and Tn increased
Number of subjects: 77467
Study 18178412 — intervention group
Group type: COMPARATOR
Intervention: BNP <840 pg/ml and Tn not increased
Number of subjects: 77467
Study 18182574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine (0.5-1.5 mg/kg)
Number of subjects: 146
Study 18182574 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 146
Study 18182574 — intervention group
Group type: EXPERIMENTAL
Intervention: ML-DS with history of TL
Number of subjects: 146
Study 18182574 — intervention group
Group type: COMPARATOR
Intervention: ML-DS without documented TL
Number of subjects: 146
Study 18184959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus therapy for 12 months
Number of subjects: 25
Study 18184959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus therapy for 12 months (in patients with lymphangioleiomyomatosis)
Number of subjects: 25
Study 18184959 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year after sirolimus therapy was discontinued
Number of subjects: 25
Study 18184959 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus therapy
Number of subjects: 25
Study 18190252 — intervention group
Group type: EXPERIMENTAL
Intervention: WNV DNA vaccine (3 doses)
Number of subjects: 15
Study 18191528 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (CRT) followed by resection
Number of subjects: 302
Study 18191528 — intervention group
Group type: COMPARATOR
Intervention: Primary resection without any pretreatment
Number of subjects: 302
Study 18191528 — intervention group
Group type: COMPARATOR
Intervention: Patients with unresectable tumours
Number of subjects: 302
Study 18191528 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (CRT)
Number of subjects: 302
Study 18194527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 targeting self-efficacy; involved a graded task and action plan development.
Number of subjects: 0
Study 18194527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 targeting anticipated consequences; involved persuasive communication with visual aids.
Number of subjects: 0
Study 18195175 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 127
Study 18195175 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 127
Study 18195220 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine 125 plaques
Number of subjects: 162
Study 18201682 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival resection combined with Tenon layer excision
Number of subjects: 30
Study 18201682 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients undergoing cataract and retinal surgery)
Number of subjects: 30
Study 18206507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg, 2 intravenous applications, 2 weeks apart)
Number of subjects: 6
Study 18206856 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) augmentation treatment for 4 weeks
Number of subjects: 19
Study 18206856 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects (no treatment)
Number of subjects: 19
Study 18212631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR) monotherapy
Number of subjects: 5
Study 18212631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus plus Tacrolimus (SIR-TAC) combination therapy
Number of subjects: 5
Study 18213379 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+1AS
Number of subjects: 2102
Study 18213379 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+3AS
Number of subjects: 2102
Study 18213379 — intervention group
Group type: EXPERIMENTAL
Intervention: 3AQ+3AS
Number of subjects: 2102
Study 18213379 — intervention group
Group type: EXPERIMENTAL
Intervention: SP+3AQ
Number of subjects: 2102
Study 18215105 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 14
Study 18216052 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD subjects
Number of subjects: 2180
Study 18216052 — intervention group
Group type: COMPARATOR
Intervention: Smoking control subjects
Number of subjects: 2180
Study 18216052 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking control subjects
Number of subjects: 2180
Study 18218852 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with retrovirally transduced hematopoietic stem/progenitor cells
Number of subjects: 0
Study 18218852 — intervention group
Group type: COMPARATOR
Intervention: Exposure to 2'-deoxy-adenosine
Number of subjects: 0
Study 18221516 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative stepped care intervention
Number of subjects: 3600
Study 18221516 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care control intervention
Number of subjects: 3600
Study 18221542 — intervention group
Group type: EXPERIMENTAL
Intervention: DC/Apo-Nec vaccine (dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells)
Number of subjects: 16
Study 18221542 — intervention group
Group type: EXPERIMENTAL
Intervention: DC/Apo-Nec vaccine
Number of subjects: 16
Study 18221542 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 promoter -1082 polymorphism analysis
Number of subjects: 16
Study 18221542 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of patients post-surgery
Number of subjects: 16
Study 18222230 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy with cisplatin and etoposide, concurrent radiation
Number of subjects: 10
Study 18222352 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stent (CAS) placement with Carotid WALLSTENT plus FilterWire EX/EZ Emboli Protection System
Number of subjects: 480
Study 18231580 — intervention group
Group type: EXPERIMENTAL
Intervention: PEV3A
Number of subjects: 30
Study 18231580 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 18235052 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D3 supplementation (1,000 mg elemental calcium plus 400 IU of vitamin D3 daily)
Number of subjects: 33951
Study 18235052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33951
Study 18237873 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon with ribavirin therapy
Number of subjects: 588
Study 18237873 — intervention group
Group type: COMPARATOR
Intervention: Null response
Number of subjects: 588
Study 18249033 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine
Number of subjects: 247
Study 18249033 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 247
Study 18249033 — intervention group
Group type: EXPERIMENTAL
Intervention: Early decrease in CA 19-9 concentration of at least 50% after two cycles of chemotherapy
Number of subjects: 247
Study 18249033 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in CA 19-9 concentration of at least 50% at nadir
Number of subjects: 247
Study 18251622 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine up to 120 mg/day
Number of subjects: 40
Study 18251622 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (not detailed in the abstract)
Number of subjects: 40
Study 18252900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 522
Study 18252900 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study 18252902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adiponectin levels
Number of subjects: 185
Study 18252902 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quartiles of adiponectin
Number of subjects: 185
Study 18253503 — intervention group
Group type: EXPERIMENTAL
Intervention: ICC-1132 vaccine (alhydrogel-adjuvanted)
Number of subjects: 51
Study 18256322 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 351
Study 18256394 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 15
Study 18256394 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular studies
Number of subjects: 15
Study 18256394 — intervention group
Group type: COMPARATOR
Intervention: Clinical investigations
Number of subjects: 15
Study 18256395 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-replacement therapy
Number of subjects: 81
Study 18256395 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (late-diagnosis and late-treatment patients)
Number of subjects: 81
Study 18284320 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 units subcutaneously once weekly until Hb > or =13 g/dl, then every 2 weeks or longer during maintenance phase.
Number of subjects: 292
Study 18284320 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa administered every other week or longer during maintenance phase.
Number of subjects: 292
Study 18284320 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa during maintenance phase.
Number of subjects: 292
Study 18284320 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa.
Number of subjects: 292
Study 18289372 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted subunit influenza vaccine (Sub/MF59; FLUAD, Novartis Vaccines)
Number of subjects: 600
Study 18289372 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted subunit influenza vaccine (Subunit; Agrippal, Novartis Vaccines)
Number of subjects: 600
Study 18289410 — intervention group
Group type: EXPERIMENTAL
Intervention: Procoagulant treatments for oral anticoagulant treatment-intracerebral haemorrhage
Number of subjects: 0
Study 18289410 — intervention group
Group type: COMPARATOR
Intervention: Standardized treatments aimed at normalization of iatrogenic coagulation impairment
Number of subjects: 0
Study 18292985 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.0 pmol kg(-1) min(-1)) during glucose infusion
Number of subjects: 9
Study 18292985 — intervention group
Group type: COMPARATOR
Intervention: Saline during glucose infusion
Number of subjects: 9
Study 18296419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vorinostat 300 mg b.i.d. 14 days/3 weeks
Number of subjects: 18
Study 18296419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vorinostat 300 mg b.i.d. 3 days/week
Number of subjects: 18
Study 18296419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vorinostat
Number of subjects: 18
Study 18297527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vorinostat 250 mg twice daily for 5 days/week/4-week cycle
Number of subjects: 13
Study 18297527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vorinostat 200 mg twice daily for 14 days/3-week cycle
Number of subjects: 13
Study 18297527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vorinostat (various doses)
Number of subjects: 13
Study 18298130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mepolizumab
Number of subjects: 105
Study 18298856 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chelation therapy with subcutaneous deferoxamine and oral deferiprone
Number of subjects: 22
Study 18299450 — intervention group
Group type: EXPERIMENTAL
Intervention: DDX3Y-specific CTLs
Number of subjects: 0
Study 18299450 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8(+) T-cell responses against DDX3Y
Number of subjects: 0
Study 18300255 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m(2) every 3 weeks and gefitinib 250 mg orally, daily
Number of subjects: 44
Study 18300255 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and gefitinib
Number of subjects: 44
Study 18301743 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine (3.8 microg haemagglutinin)
Number of subjects: 40
Study 18301743 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine (3.8 microg haemagglutinin)
Number of subjects: 40
Study 18302747 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg, one tablet daily for 4 months
Number of subjects: 33
Study 18302747 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg, one tablet daily for > 4 months
Number of subjects: 33
Study 18302747 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole treatment
Number of subjects: 33
Study 18303488 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexarotene (75 mg/d)
Number of subjects: 25
Study 18304017 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO practice in responding centres
Number of subjects: 39
Study 18304017 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual respondent ECMO experience
Number of subjects: 39
Study 18304017 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for ECMO use
Number of subjects: 39
Study 18304017 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to conduct ECMO
Number of subjects: 39
Study 18304017 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of ECMO as a useful tool
Number of subjects: 39
Study 18305939 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 56
Study 18307808 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized TCM acupuncture
Number of subjects: 640
Study 18307808 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized TCM acupuncture
Number of subjects: 640
Study 18307808 — intervention group
Group type: COMPARATOR
Intervention: Simulated acupuncture (control)
Number of subjects: 640
Study 18307808 — intervention group
Group type: COMPARATOR
Intervention: Continued usual medical care
Number of subjects: 640
Study 18308865 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD 2
Number of subjects: 117
Study 18308865 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD 3
Number of subjects: 117
Study 18308865 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 117
Study 18310179 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological study (low risk)
Number of subjects: 200
Study 18310179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine study (high risk)
Number of subjects: 200
Study 18310179 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealing telephone number (behavioral measure)
Number of subjects: 200
Study 18310179 — intervention group
Group type: COMPARATOR
Intervention: General consent to studies
Number of subjects: 200
Study 18312048 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) methylphenidate
Number of subjects: 607
Study 18312048 — intervention group
Group type: COMPARATOR
Intervention: Osmotic release oral system (OROS) methylphenidate
Number of subjects: 607
Study 18312048 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IR and OROS methylphenidate
Number of subjects: 607
Study 18315448 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 6
Study 18315876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5,000 IU once daily for a median duration of 7 days (interquartile range, 4 to 12 days)
Number of subjects: 138
Study 18315876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 5,000 IU once daily
Number of subjects: 138
Study 18316697 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal hysteresis (CH) in glaucoma group (8.8 mm Hg)
Number of subjects: 100
Study 18316697 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness (CCT) in glaucoma group (532 microm)
Number of subjects: 100
Study 18316697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean cup depth increase during IOP elevation in glaucoma group (29.8 microm)
Number of subjects: 100
Study 18316697 — intervention group
Group type: COMPARATOR
Intervention: Mean cup depth increase during IOP elevation in control group (36.1 microm)
Number of subjects: 100
Study 18316697 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal hysteresis (CH) correlation with mean cup depth increase
Number of subjects: 100
Study 18316697 — intervention group
Group type: EXPERIMENTAL
Intervention: Central corneal thickness (CCT) correlation with mean cup depth increase
Number of subjects: 100
Study 18316697 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial length correlation with mean cup depth increase
Number of subjects: 100
Study 18316697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular pulse amplitude correlation with mean cup depth increase
Number of subjects: 100
Study 18316697 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical equivalent correlation with mean cup depth increase
Number of subjects: 100
Study 18328118 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (subcutaneous, every-other-week)
Number of subjects: 277
Study 18331634 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB1 Gly389 polymorphism
Number of subjects: 628
Study 18331634 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB1 Gly389 polymorphism (Gly/Gly vs. Arg/Arg)
Number of subjects: 628
Study 18331634 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB1 Gly389 polymorphism in women without obstructive CAD
Number of subjects: 628
Study 18331634 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRB3 Arg64 variant in women without obstructive CAD
Number of subjects: 628
Study 18331634 — intervention group
Group type: COMPARATOR
Intervention: No genetic associations
Number of subjects: 628